GSK team clinches positive trial for the first potential new TB vaccine in a century — with millions of lives at stake
A GlaxoSmithKline crew of investigators has completed their analysis of a Phase IIb trial for what they believe could be the first big breakthrough in the tuberculosis vaccine field in close to 100 years. And they say the final results justify their enthusiasm for final rounds of studies aimed at studying a jab that has the potential to slash the more than 1.5 million deaths per year attributed to TB.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.